JP2019528280A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528280A5 JP2019528280A5 JP2019508953A JP2019508953A JP2019528280A5 JP 2019528280 A5 JP2019528280 A5 JP 2019528280A5 JP 2019508953 A JP2019508953 A JP 2019508953A JP 2019508953 A JP2019508953 A JP 2019508953A JP 2019528280 A5 JP2019528280 A5 JP 2019528280A5
- Authority
- JP
- Japan
- Prior art keywords
- hiv
- inhibitor
- tenofovir
- inhibitors
- additional therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000725303 Human immunodeficiency virus Species 0.000 claims 53
- 239000003112 inhibitor Substances 0.000 claims 52
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 46
- 229960004556 tenofovir Drugs 0.000 claims 36
- 239000003814 drug Substances 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 25
- 229940124597 therapeutic agent Drugs 0.000 claims 25
- 102100034343 Integrase Human genes 0.000 claims 17
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 16
- 229960001355 tenofovir disoproxil Drugs 0.000 claims 16
- JFVZFKDSXNQEJW-CQSZACIVSA-N tenofovir disoproxil Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N JFVZFKDSXNQEJW-CQSZACIVSA-N 0.000 claims 16
- 239000002777 nucleoside Substances 0.000 claims 15
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 14
- 229940121649 protein inhibitor Drugs 0.000 claims 12
- 239000012268 protein inhibitor Substances 0.000 claims 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 11
- IKKXOSBHLYMWAE-QRPMWFLTSA-N islatravir Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@H]1C[C@H](O)[C@](CO)(C#C)O1 IKKXOSBHLYMWAE-QRPMWFLTSA-N 0.000 claims 10
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 claims 10
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 7
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims 6
- 229940099797 HIV integrase inhibitor Drugs 0.000 claims 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 6
- 229960000531 abacavir sulfate Drugs 0.000 claims 6
- WMHSRBZIJNQHKT-FFKFEZPRSA-N abacavir sulfate Chemical compound OS(O)(=O)=O.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 WMHSRBZIJNQHKT-FFKFEZPRSA-N 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 6
- 210000000234 capsid Anatomy 0.000 claims 6
- 229960000366 emtricitabine Drugs 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 6
- 239000003084 hiv integrase inhibitor Substances 0.000 claims 6
- 239000004030 hiv protease inhibitor Substances 0.000 claims 6
- 230000005764 inhibitory process Effects 0.000 claims 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 4
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims 4
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 4
- 108091007960 PI3Ks Proteins 0.000 claims 4
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 4
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 102100033391 ATP-dependent RNA helicase DDX3X Human genes 0.000 claims 3
- 101710156069 ATP-dependent RNA helicase DDX3X Proteins 0.000 claims 3
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 claims 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 3
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 3
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 3
- 229940126074 CDK kinase inhibitor Drugs 0.000 claims 3
- 102100024310 COMM domain-containing protein 1 Human genes 0.000 claims 3
- 101710155310 COMM domain-containing protein 1 Proteins 0.000 claims 3
- 101100383153 Caenorhabditis elegans cdk-9 gene Proteins 0.000 claims 3
- 108010078546 Complement C5a Proteins 0.000 claims 3
- 102000016550 Complement Factor H Human genes 0.000 claims 3
- 108010053085 Complement Factor H Proteins 0.000 claims 3
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 claims 3
- 108010072220 Cyclophilin A Proteins 0.000 claims 3
- 229940122546 Deoxycytidine kinase inhibitor Drugs 0.000 claims 3
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims 3
- 101710177291 Gag polyprotein Proteins 0.000 claims 3
- 108060003393 Granulin Proteins 0.000 claims 3
- 108700025685 HIV Enhancer Proteins 0.000 claims 3
- 229940126154 HIV entry inhibitor Drugs 0.000 claims 3
- 229940126252 HIV maturation inhibitor Drugs 0.000 claims 3
- 229940033330 HIV vaccine Drugs 0.000 claims 3
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 3
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 claims 3
- 108010064899 Human Immunodeficiency Virus Ribonuclease H Proteins 0.000 claims 3
- 108700020134 Human immunodeficiency virus 1 nef Proteins 0.000 claims 3
- 229940123038 Integrin antagonist Drugs 0.000 claims 3
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 claims 3
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 claims 3
- 229940113306 Ligase inhibitor Drugs 0.000 claims 3
- 101710125418 Major capsid protein Proteins 0.000 claims 3
- 108010007843 NADH oxidase Proteins 0.000 claims 3
- 102000011931 Nucleoproteins Human genes 0.000 claims 3
- 108010061100 Nucleoproteins Proteins 0.000 claims 3
- 229940087098 Oxidase inhibitor Drugs 0.000 claims 3
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 claims 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 3
- 102000006437 Proprotein Convertases Human genes 0.000 claims 3
- 108010044159 Proprotein Convertases Proteins 0.000 claims 3
- 101710150344 Protein Rev Proteins 0.000 claims 3
- 101710149951 Protein Tat Proteins 0.000 claims 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 3
- 102000015097 RNA Splicing Factors Human genes 0.000 claims 3
- 108010039259 RNA Splicing Factors Proteins 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims 3
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims 3
- 101710201961 Virion infectivity factor Proteins 0.000 claims 3
- 230000003281 allosteric effect Effects 0.000 claims 3
- 230000003197 catalytic effect Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229940125507 complex inhibitor Drugs 0.000 claims 3
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 3
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 3
- 238000006471 dimerization reaction Methods 0.000 claims 3
- 239000003968 dna methyltransferase inhibitor Substances 0.000 claims 3
- 239000003623 enhancer Substances 0.000 claims 3
- 229940124784 gp41 inhibitor Drugs 0.000 claims 3
- 239000002835 hiv fusion inhibitor Substances 0.000 claims 3
- 238000009169 immunotherapy Methods 0.000 claims 3
- 239000012678 infectious agent Substances 0.000 claims 3
- 150000007529 inorganic bases Chemical class 0.000 claims 3
- 239000002850 integrase inhibitor Substances 0.000 claims 3
- 229940124524 integrase inhibitor Drugs 0.000 claims 3
- 102000006495 integrins Human genes 0.000 claims 3
- 108010044426 integrins Proteins 0.000 claims 3
- 239000000436 ligase inhibitor Substances 0.000 claims 3
- 108010089520 pol Gene Products Proteins 0.000 claims 3
- 229920001983 poloxamer Polymers 0.000 claims 3
- 229960000502 poloxamer Drugs 0.000 claims 3
- 229920001993 poloxamer 188 Polymers 0.000 claims 3
- 229940044519 poloxamer 188 Drugs 0.000 claims 3
- 229940113115 polyethylene glycol 200 Drugs 0.000 claims 3
- 238000006116 polymerization reaction Methods 0.000 claims 3
- 230000037452 priming Effects 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 239000002464 receptor antagonist Substances 0.000 claims 3
- 229940044551 receptor antagonist Drugs 0.000 claims 3
- 239000012313 reversal agent Substances 0.000 claims 3
- 230000008685 targeting Effects 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 108700026220 vif Genes Proteins 0.000 claims 3
- 101150059019 vif gene Proteins 0.000 claims 3
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims 2
- 229940126190 DNA methyltransferase inhibitor Drugs 0.000 claims 2
- 229940123723 Protein disulfide isomerase inhibitor Drugs 0.000 claims 2
- 229940122613 Ribonuclease H inhibitor Drugs 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- MPSGQQOHTJUJKB-QUBYGPBYSA-N [(2r,5r)-5-(6-aminopurin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxymethylphosphonic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](OCP(O)(O)=O)C=C1F MPSGQQOHTJUJKB-QUBYGPBYSA-N 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 229960001627 lamivudine Drugs 0.000 claims 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 2
- OCJRRXHWPBXZSU-BNCZGPJRSA-N rovafovir etalafenamide Chemical group O([P@@](=O)(CO[C@@H]1C=C(F)[C@@H](O1)N1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OCC)C1=CC=CC=C1 OCJRRXHWPBXZSU-BNCZGPJRSA-N 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 102000016736 Cyclin Human genes 0.000 claims 1
- 108050006400 Cyclin Proteins 0.000 claims 1
- 229920002517 Poloxamer 338 Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 claims 1
- -1 and optionally Polymers 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 239000003394 isomerase inhibitor Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108020003519 protein disulfide isomerase Proteins 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662377312P | 2016-08-19 | 2016-08-19 | |
| US62/377,312 | 2016-08-19 | ||
| US201762457555P | 2017-02-10 | 2017-02-10 | |
| US62/457,555 | 2017-02-10 | ||
| PCT/US2017/047416 WO2018035359A1 (en) | 2016-08-19 | 2017-08-17 | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020048130A Division JP2020111592A (ja) | 2016-08-19 | 2020-03-18 | Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528280A JP2019528280A (ja) | 2019-10-10 |
| JP2019528280A5 true JP2019528280A5 (https=) | 2019-12-12 |
| JP6716785B2 JP6716785B2 (ja) | 2020-07-01 |
Family
ID=59714166
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508953A Active JP6716785B2 (ja) | 2016-08-19 | 2017-08-17 | Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 |
| JP2020048130A Withdrawn JP2020111592A (ja) | 2016-08-19 | 2020-03-18 | Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 |
| JP2020175151A Pending JP2021008516A (ja) | 2016-08-19 | 2020-10-19 | Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 |
| JP2022172416A Withdrawn JP2023011754A (ja) | 2016-08-19 | 2022-10-27 | Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 |
| JP2024148326A Withdrawn JP2024170471A (ja) | 2016-08-19 | 2024-08-30 | Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020048130A Withdrawn JP2020111592A (ja) | 2016-08-19 | 2020-03-18 | Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 |
| JP2020175151A Pending JP2021008516A (ja) | 2016-08-19 | 2020-10-19 | Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 |
| JP2022172416A Withdrawn JP2023011754A (ja) | 2016-08-19 | 2022-10-27 | Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 |
| JP2024148326A Withdrawn JP2024170471A (ja) | 2016-08-19 | 2024-08-30 | Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 |
Country Status (43)
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2729448B1 (en) | 2011-07-06 | 2015-09-09 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| WO2015130964A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Therapeutic compounds |
| KR20230011471A (ko) | 2016-08-19 | 2023-01-20 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물 |
| AR112412A1 (es) * | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| TWI687415B (zh) * | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| US10836746B2 (en) * | 2018-02-15 | 2020-11-17 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2019161280A1 (en) | 2018-02-16 | 2019-08-22 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
| WO2019246545A1 (en) * | 2018-06-21 | 2019-12-26 | Drexel University | Small-molecule hiv-1 capsid protein inhibitors and methods using same |
| CN120053445A (zh) | 2018-07-16 | 2025-05-30 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| JP7386230B2 (ja) * | 2018-08-09 | 2023-11-24 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| WO2020053811A1 (en) | 2018-09-14 | 2020-03-19 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| JP7433303B2 (ja) | 2018-09-20 | 2024-02-19 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| ES2970251T3 (es) * | 2018-10-22 | 2024-05-27 | Univ Nebraska | Profármacos antivirales y nanoformulaciones de los mismos |
| MX2021004593A (es) | 2018-10-24 | 2021-06-15 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. |
| US20210395262A1 (en) | 2018-10-24 | 2021-12-23 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US20210393633A1 (en) | 2018-10-25 | 2021-12-23 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| EP3873607B1 (en) * | 2018-10-29 | 2023-11-29 | VIIV Healthcare UK (No.5) Limited | Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication |
| US20210379071A1 (en) | 2018-11-05 | 2021-12-09 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| WO2020095177A1 (en) * | 2018-11-05 | 2020-05-14 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| SG11202107145SA (en) | 2019-01-25 | 2021-08-30 | Univ Brown | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders |
| UY38559A (es) | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| WO2020197991A1 (en) | 2019-03-22 | 2020-10-01 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| EP3962603A1 (en) | 2019-04-30 | 2022-03-09 | ViiV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| RU2717101C1 (ru) | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения |
| LT3986561T (lt) * | 2019-06-19 | 2024-04-25 | VIIV Healthcare UK (No.5) Limited | Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai |
| US20220389007A1 (en) | 2019-10-01 | 2022-12-08 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| ES2974657T3 (es) * | 2019-10-01 | 2024-07-01 | Viiv Healthcare Uk No 5 Ltd | Derivados de n-substituido-6-oxo-1,6-dihidropirimidina-2-ilo como inhibidores de la replicación del virus de inmunodeficiencia humana |
| TW202128648A (zh) | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| WO2021070054A1 (en) | 2019-10-08 | 2021-04-15 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| TWI854067B (zh) | 2019-11-26 | 2024-09-01 | 美商基利科學股份有限公司 | 預防hiv之蛋白殼抑制劑 |
| TWI902729B (zh) | 2019-11-28 | 2025-11-01 | 日商鹽野義製藥股份有限公司 | 以組合整合酶阻礙劑及抗ｈｉｖ藥為特徵之ｈｉｖ感染症的預防及治療用醫藥 |
| JP2023503672A (ja) | 2019-11-29 | 2023-01-31 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合ピリジン環誘導体、その調製方法及びその医薬的応用 |
| CN113304166B (zh) * | 2020-02-27 | 2022-10-14 | 河南真实生物科技有限公司 | 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途 |
| KR20220151655A (ko) | 2020-03-06 | 2022-11-15 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제 |
| JP2023517312A (ja) | 2020-03-06 | 2023-04-25 | ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド | ヒト免疫不全ウイルスの複製阻害剤 |
| US11718637B2 (en) | 2020-03-20 | 2023-08-08 | Gilead Sciences, Inc. | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same |
| CN115397424A (zh) | 2020-04-15 | 2022-11-25 | Viiv保健英国第五有限公司 | 人类免疫缺陷病毒复制的抑制剂 |
| EP4153181A1 (en) | 2020-05-21 | 2023-03-29 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
| PL4172157T3 (pl) * | 2020-06-25 | 2026-03-23 | Gilead Sciences, Inc. | Inhibitory kapsydu w leczeniu hiv |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| CN116437958A (zh) | 2020-11-11 | 2023-07-14 | 吉利德科学公司 | 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法 |
| TW202237146A (zh) * | 2021-01-25 | 2022-10-01 | 美商布里生物科學股份有限公司 | 使用腺苷衍生物及衣殼抑制劑之hiv組合療法 |
| CN118159529A (zh) | 2021-05-28 | 2024-06-07 | 江苏恒瑞医药股份有限公司 | 一种稠合吡啶环衍生物的可药用盐、晶型及其制备方法 |
| KR20230019059A (ko) | 2021-07-30 | 2023-02-07 | (주) 에빅스젠 | 연전초 추출물을 유효성분으로 포함하는, 바이러스성 질환 완화 및 개선용 조성물 |
| KR20230018690A (ko) | 2021-07-30 | 2023-02-07 | (주) 에빅스젠 | 둥근이질풀 추출물을 유효성분으로 포함하는, 바이러스성 질환 치료 및 개선용 조성물 |
| US20240423985A1 (en) * | 2021-10-13 | 2024-12-26 | Viiv Healthcare Uk (No.5) Limit-Ed | Inhibitors of human immunodeficiency virus replication |
| DK4445900T3 (da) | 2021-12-03 | 2025-08-18 | Gilead Sciences Inc | Terapeutiske forbindelser til hiv-virusinfektion |
| WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| JP7765637B2 (ja) * | 2021-12-03 | 2025-11-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖウイルス感染症のための治療化合物 |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| TWI867601B (zh) * | 2022-07-01 | 2024-12-21 | 美商基利科學股份有限公司 | 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物 |
| KR20250051732A (ko) | 2022-08-26 | 2025-04-17 | 길리애드 사이언시즈, 인코포레이티드 | 광범위 중화 항체를 위한 투여 및 일정 요법 |
| EP4598934A1 (en) | 2022-10-04 | 2025-08-13 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| KR20240061218A (ko) | 2022-10-31 | 2024-05-08 | 주식회사 이보드 | 복합 단열재 및 제조방법 |
| CN120958007A (zh) | 2023-01-30 | 2025-11-14 | 默沙东有限责任公司 | 4'-取代核苷逆转录酶抑制剂的前药 |
| US20240390349A1 (en) | 2023-04-19 | 2024-11-28 | Gilead Sciences, Inc. | Dosing regimen of capsid inhibitor |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| CN121399106A (zh) | 2023-05-31 | 2026-01-23 | 吉利德科学公司 | 制备hiv衣壳抑制剂的方法 |
| KR20260018877A (ko) | 2023-05-31 | 2026-02-09 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 치료에 유용한 화합물의 고체 형태 |
| CN116675675A (zh) * | 2023-06-05 | 2023-09-01 | 北京康立生医药技术开发有限公司 | 一种艾滋病治疗药物来那卡帕韦中间体化合物的制备方法 |
| AR132951A1 (es) | 2023-06-15 | 2025-08-13 | Viiv Healthcare Uk No 5 Ltd | Métodos e intermedios para preparar compuestos |
| KR20260046169A (ko) | 2023-07-28 | 2026-04-06 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료 및 예방을 위한 레나카파비르 주간 투여 레지먼 |
| TW202513072A (zh) | 2023-08-15 | 2025-04-01 | 美商基利科學股份有限公司 | 比替拉韋及利那卡帕韋之醫藥配方 |
| EP4529922A1 (en) | 2023-09-29 | 2025-04-02 | Gilead Sciences, Inc. | Pharmaceutical formulations of bictegravir and lenacapavir |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| KR20250040288A (ko) | 2023-09-15 | 2025-03-24 | 민영호 | 복합 단열재 |
| WO2025080850A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025080863A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| TW202515549A (zh) | 2023-10-11 | 2025-04-16 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| US20250230163A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US12594276B2 (en) | 2024-02-05 | 2026-04-07 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| WO2025184452A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025184609A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Antiviral compounds |
| US20250296932A1 (en) | 2024-03-01 | 2025-09-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| US20250367386A1 (en) | 2024-05-14 | 2025-12-04 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| WO2025240393A1 (en) | 2024-05-14 | 2025-11-20 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| WO2025240385A1 (en) | 2024-05-14 | 2025-11-20 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| WO2025240389A1 (en) | 2024-05-14 | 2025-11-20 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| US20250367384A1 (en) | 2024-05-14 | 2025-12-04 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| US20260007683A1 (en) | 2024-06-14 | 2026-01-08 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2025264995A1 (en) * | 2024-06-21 | 2025-12-26 | Gilead Sciences, Inc. | Formulations of an hiv capsid inhibitor |
| WO2026006521A1 (en) | 2024-06-27 | 2026-01-02 | Gilead Sciences, Inc. | Oral tablet formulations |
| WO2026020086A1 (en) | 2024-07-19 | 2026-01-22 | Gilead Sciences, Inc. | Methods and pharmaceutical formulations for treating viral infections |
| WO2026076265A1 (en) | 2024-10-03 | 2026-04-09 | Gilead Sciences, Inc. | Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| ATE131825T1 (de) | 1990-06-13 | 1996-01-15 | Arnold Glazier | Phosphorylierte prodrugs |
| EP0481214B1 (en) | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| CZ304734B6 (cs) | 2000-07-21 | 2014-09-10 | Gilead Sciences, Inc. | Způsob přípravy 9-[2-(fosfonomethoxy)propyl]adeninu a 9-[2-(fosfonomethoxy)ethyl]adeninu |
| JP4300108B2 (ja) | 2001-06-27 | 2009-07-22 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのピロリジン類 |
| DE60221983T2 (de) | 2001-06-27 | 2008-05-15 | Smithkline Beecham Corp. | Fluorpyrrolidine als dipeptidyl-peptidase inhibitoren |
| EP1441734B1 (en) | 2001-10-26 | 2007-02-28 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase |
| US7642277B2 (en) | 2002-12-04 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
| WO2004071448A2 (en) | 2003-02-12 | 2004-08-26 | Transtech Pharma Inc. | Substituted azole derivatives as inhibitors of protein tyrosine phosphatases |
| EP2359833A1 (en) | 2003-04-25 | 2011-08-24 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| EP1737881B1 (en) | 2004-02-27 | 2009-06-24 | Schering Corporation | Novel compounds as inhibitors of hepatitis c virus ns3 serine protease |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| ME03423B (me) | 2004-07-27 | 2020-01-20 | Gilead Sciences Inc | Fosfonatni analozi jedinjenja hiv inhibitora |
| US8067587B2 (en) | 2005-07-28 | 2011-11-29 | Lenroc Company | Process for the production of monoalkali metal cyanurates |
| KR20080035576A (ko) | 2005-08-05 | 2008-04-23 | 아스트라제네카 아베 | 트리사이클릭 벤즈이미다졸 및 대사체 글루타메이트 수용체조절제로서 이들의 용도 |
| EP1981854B1 (en) | 2005-12-14 | 2011-06-01 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| MX2008013238A (es) | 2006-04-12 | 2008-10-21 | Merck & Co Inc | Antagonistas de los canales de calcio de tipo t de piridil amida. |
| US7647464B2 (en) | 2006-04-28 | 2010-01-12 | At&T Intellectual Property, I,L.P. | Methods, systems, and products for recording media to a restoration server |
| WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| US8124811B2 (en) | 2007-03-20 | 2012-02-28 | Allylix, Inc. | Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one |
| CA2681718A1 (en) | 2007-03-23 | 2008-10-02 | University Of Massachusetts | Hiv-1 protease inhibitors |
| AP2009005073A0 (en) | 2007-06-29 | 2009-12-31 | Gilead Sciences Inc | Antiviral compounds |
| SI2175857T1 (sl) | 2007-07-12 | 2014-01-31 | Janssen R&D Ireland | Kristalna oblika (E) 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino) 2-pirimidinil)amino)benzonitrila |
| AU2008277377B2 (en) | 2007-07-19 | 2013-08-01 | Msd Italia S.R.L. | Macrocyclic compounds as antiviral agents |
| JP2011500808A (ja) | 2007-10-24 | 2011-01-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 複素環アミドｔ型カルシウムチャネルアンタゴニスト |
| CN101910133A (zh) | 2007-10-24 | 2010-12-08 | 默沙东公司 | 杂环苯基酰胺t-型钙通道拮抗剂 |
| MX2010005334A (es) | 2007-11-16 | 2010-05-27 | Boehringer Ingelheim Int | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. |
| US8324199B2 (en) | 2008-03-13 | 2012-12-04 | Bristol-Myers Squibb Company | Pyridazine derivatives as factor xia inhibitors |
| ES2467108T3 (es) | 2008-12-09 | 2014-06-11 | Gilead Sciences, Inc. | Moduladores de receptores tipo toll |
| CN102414217A (zh) | 2009-02-25 | 2012-04-11 | 彼格泰格私人有限公司 | 用于检测基孔肯雅病毒的探针和引物 |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
| WO2011143772A1 (en) | 2010-05-21 | 2011-11-24 | Boehringer Ingelheim International Gmbh | Inhibitors of hiv replication |
| KR20130124291A (ko) | 2010-07-02 | 2013-11-13 | 길리애드 사이언시즈, 인코포레이티드 | Ｈｉｖ 항바이러스 화합물로서의 2-퀴놀리닐-아세트산 유도체 |
| AP2013006706A0 (en) | 2010-07-02 | 2013-02-28 | Gilead Sciences Inc | Napht-2-ylacetic acid derivatives to treat AIDS |
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| ME02754B (me) | 2011-03-23 | 2018-01-20 | Trevena Inc | Ligandi opioidnih receptora i postupci njihove upotrebe i pripreme |
| BR112013027096A2 (pt) | 2011-04-21 | 2016-12-27 | Gilead Sciences Inc | compostos de benzotiazol e seu uso farmacêutico |
| EP2729448B1 (en) | 2011-07-06 | 2015-09-09 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| HRP20161696T4 (hr) | 2011-08-16 | 2023-10-13 | Gilead Sciences, Inc. | Tenofovir alafenamid hemifumarat |
| US9399645B2 (en) | 2011-12-20 | 2016-07-26 | Boehringer Ingelheim International Gmbh | Inhibitors of HIV replication |
| ES2571479T3 (es) | 2012-04-20 | 2016-05-25 | Gilead Sciences Inc | Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH |
| GB201213087D0 (en) | 2012-07-24 | 2012-09-05 | Medical Res Council | Inhibition of HIV-1 infection |
| WO2014028931A2 (en) | 2012-08-17 | 2014-02-20 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| EA030003B1 (ru) | 2012-12-21 | 2018-06-29 | Джилид Сайэнс, Инк. | Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции |
| US20140221378A1 (en) | 2012-12-27 | 2014-08-07 | Japan Tobacco Inc. | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR |
| CA2896244C (en) | 2013-01-09 | 2017-07-04 | Gilead Sciences, Inc. | 5-membered heteroaryls and their use as antiviral agents |
| TW201443037A (zh) * | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| CA2897268C (en) | 2013-01-09 | 2018-12-04 | Gilead Sciences, Inc. | Therapeutic compounds for the treatment of viral infections |
| EP2769722A1 (en) | 2013-02-22 | 2014-08-27 | Ruprecht-Karls-Universität Heidelberg | Compounds for use in inhibiting HIV capsid assembly |
| US20140296266A1 (en) | 2013-03-01 | 2014-10-02 | Gilead Sciences, Inc. | Therapeutic compounds |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| GB201312991D0 (en) | 2013-07-19 | 2013-09-04 | Isis Innovation | Process |
| EP3060554A1 (en) | 2013-10-24 | 2016-08-31 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| WO2015130964A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| PT3186239T (pt) | 2014-08-29 | 2019-01-10 | Gilead Sciences Inc | Agentes antirretrovirais |
| US9855230B2 (en) | 2014-09-09 | 2018-01-02 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| ES2735087T3 (es) | 2014-12-24 | 2019-12-16 | Gilead Sciences Inc | Compuestos de pirimidina fusionados para el tratamiento de VIH |
| TWI699355B (zh) | 2014-12-24 | 2020-07-21 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| BR112017022605A2 (pt) | 2015-04-23 | 2018-07-17 | Viiv Healthcare Uk No 5 Ltd | ?composto, composição, e, método para tratamento de infecção por hiv?. |
| CN107995910A (zh) | 2015-04-23 | 2018-05-04 | Viiv保健英国第五有限公司 | 人免疫缺陷病毒复制的抑制剂 |
| KR101974793B1 (ko) * | 2015-07-06 | 2019-05-02 | 길리애드 사이언시즈, 인코포레이티드 | Cot 조정제 및 그의 사용 방법 |
| US10171985B1 (en) | 2015-07-22 | 2019-01-01 | Ginko LLC | Method and apparatus for data sharing |
| KR20230011471A (ko) | 2016-08-19 | 2023-01-20 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물 |
| UY37592A (es) | 2017-02-06 | 2018-08-31 | Gilead Sciences Inc | Compuestos inhibidores del vih |
| TW201906834A (zh) | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| TWI687415B (zh) * | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| US10836746B2 (en) | 2018-02-15 | 2020-11-17 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2019161280A1 (en) | 2018-02-16 | 2019-08-22 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
| US10911396B2 (en) | 2018-06-28 | 2021-02-02 | Paypal, Inc. | Mid-tier messaging system |
| CN120053445A (zh) | 2018-07-16 | 2025-05-30 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| TWI854067B (zh) | 2019-11-26 | 2024-09-01 | 美商基利科學股份有限公司 | 預防hiv之蛋白殼抑制劑 |
| PL4172157T3 (pl) | 2020-06-25 | 2026-03-23 | Gilead Sciences, Inc. | Inhibitory kapsydu w leczeniu hiv |
-
2017
- 2017-08-17 KR KR1020237000165A patent/KR20230011471A/ko not_active Ceased
- 2017-08-17 TW TW109146483A patent/TW202138365A/zh unknown
- 2017-08-17 DK DK19178148.3T patent/DK3597646T3/da active
- 2017-08-17 SI SI201730077T patent/SI3347352T1/sl unknown
- 2017-08-17 TW TW108108262A patent/TWI715944B/zh active
- 2017-08-17 HU HUE19178148A patent/HUE063811T2/hu unknown
- 2017-08-17 WO PCT/US2017/047416 patent/WO2018035359A1/en not_active Ceased
- 2017-08-17 ES ES19178148T patent/ES2954514T3/es active Active
- 2017-08-17 KR KR1020257017413A patent/KR20250085838A/ko active Pending
- 2017-08-17 BR BR112018071678-2A patent/BR112018071678B1/pt active Search and Examination
- 2017-08-17 EP EP23179840.6A patent/EP4265299A3/en active Pending
- 2017-08-17 SG SG11201808944QA patent/SG11201808944QA/en unknown
- 2017-08-17 TW TW113111532A patent/TW202504608A/zh unknown
- 2017-08-17 PL PL17758388T patent/PL3347352T3/pl unknown
- 2017-08-17 TW TW106127987A patent/TWI664966B/zh active
- 2017-08-17 EP EP17758388.7A patent/EP3347352B1/en active Active
- 2017-08-17 JO JOJO/P/2018/0098A patent/JOP20180098A1/ar unknown
- 2017-08-17 DK DK17758388.7T patent/DK3347352T3/da active
- 2017-08-17 PH PH1/2021/552802A patent/PH12021552802A1/en unknown
- 2017-08-17 US US15/680,041 patent/US10071985B2/en active Active
- 2017-08-17 KR KR1020197007456A patent/KR102180740B1/ko active Active
- 2017-08-17 CN CN202411603090.3A patent/CN119462611A/zh active Pending
- 2017-08-17 PE PE2019000375A patent/PE20190910A1/es unknown
- 2017-08-17 BR BR122020001791-0A patent/BR122020001791B1/pt active IP Right Grant
- 2017-08-17 JP JP2019508953A patent/JP6716785B2/ja active Active
- 2017-08-17 TW TW112100805A patent/TWI853404B/zh active
- 2017-08-17 MX MX2018012905A patent/MX369307B/es active IP Right Grant
- 2017-08-17 CR CR20190084A patent/CR20190084A/es unknown
- 2017-08-17 MY MYPI2019000877A patent/MY191466A/en unknown
- 2017-08-17 HU HUE17758388A patent/HUE045137T2/hu unknown
- 2017-08-17 UA UAA201901739 patent/UA121630C2/uk unknown
- 2017-08-17 NZ NZ750706A patent/NZ750706A/en unknown
- 2017-08-17 FI FIEP19178148.3T patent/FI3597646T3/fi active
- 2017-08-17 SG SG10201912535VA patent/SG10201912535VA/en unknown
- 2017-08-17 LT LTEP17758388.7T patent/LT3347352T/lt unknown
- 2017-08-17 PT PT17758388T patent/PT3347352T/pt unknown
- 2017-08-17 ES ES17758388T patent/ES2746374T3/es active Active
- 2017-08-17 PL PL19178148.3T patent/PL3597646T3/pl unknown
- 2017-08-17 HR HRP20231018TT patent/HRP20231018T1/hr unknown
- 2017-08-17 CN CN201780063636.2A patent/CN109890808B/zh active Active
- 2017-08-17 CN CN202010662665.4A patent/CN111793061B/zh active Active
- 2017-08-17 UY UY0001037367A patent/UY37367A/es not_active Application Discontinuation
- 2017-08-17 MA MA42795A patent/MA42795B1/fr unknown
- 2017-08-17 EP EP19178148.3A patent/EP3597646B1/en active Active
- 2017-08-17 CA CA3021227A patent/CA3021227C/en active Active
- 2017-08-17 MA MA050673A patent/MA50673A/fr unknown
- 2017-08-17 LT LTEP19178148.3T patent/LT3597646T/lt unknown
- 2017-08-17 AU AU2017312102A patent/AU2017312102B2/en active Active
- 2017-08-17 KR KR1020207032788A patent/KR20200131351A/ko not_active Ceased
- 2017-08-17 HK HK18116015.7A patent/HK1256904B/en unknown
- 2017-08-17 PE PE2020000548A patent/PE20211427A1/es unknown
- 2017-08-17 SI SI201731404T patent/SI3597646T1/sl unknown
- 2017-08-17 KR KR1020247014103A patent/KR20240070646A/ko not_active Ceased
- 2017-08-17 PT PT191781483T patent/PT3597646T/pt unknown
-
2018
- 2018-06-25 US US16/016,718 patent/US10654827B2/en active Active
- 2018-12-16 JO JOP/2018/0123A patent/JOP20180123A1/ar unknown
-
2019
- 2019-02-04 IL IL264644A patent/IL264644B/en active IP Right Grant
- 2019-02-15 PH PH12019500335A patent/PH12019500335A1/en unknown
- 2019-02-15 EC ECSENADI201911209A patent/ECSP19011209A/es unknown
- 2019-02-15 CO CONC2019/0001379A patent/CO2019001379A2/es unknown
- 2019-02-15 CL CL2019000415A patent/CL2019000415A1/es unknown
- 2019-02-15 DO DO2019000033A patent/DOP2019000033A/es unknown
- 2019-02-18 SA SA519401123A patent/SA519401123B1/ar unknown
- 2019-03-07 ZA ZA2019/01430A patent/ZA201901430B/en unknown
- 2019-09-13 CY CY20191100958T patent/CY1122296T1/el unknown
- 2019-11-25 US US16/694,332 patent/US11993583B2/en active Active
-
2020
- 2020-03-18 JP JP2020048130A patent/JP2020111592A/ja not_active Withdrawn
- 2020-04-02 AU AU2020202331A patent/AU2020202331C1/en active Active
- 2020-10-19 JP JP2020175151A patent/JP2021008516A/ja active Pending
-
2021
- 2021-08-26 AU AU2021221855A patent/AU2021221855B2/en active Active
-
2022
- 2022-10-27 JP JP2022172416A patent/JP2023011754A/ja not_active Withdrawn
- 2022-12-13 LU LU00292C patent/LUC00292I2/fr unknown
- 2022-12-14 HU HUS2200053C patent/HUS2200053I1/hu unknown
- 2022-12-16 NO NO2022059C patent/NO2022059I1/no unknown
- 2022-12-16 FR FR22C1063C patent/FR22C1063I2/fr active Active
- 2022-12-22 CY CY2022039C patent/CY2022039I2/el unknown
-
2023
- 2023-01-05 LT LTPA2023501C patent/LTC3347352I2/lt unknown
- 2023-01-11 NL NL301212C patent/NL301212I2/nl unknown
- 2023-11-27 AU AU2023271739A patent/AU2023271739B2/en active Active
-
2024
- 2024-04-11 US US18/632,593 patent/US20240376077A1/en active Pending
- 2024-08-30 JP JP2024148326A patent/JP2024170471A/ja not_active Withdrawn
-
2025
- 2025-11-21 AU AU2025271141A patent/AU2025271141A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528280A5 (https=) | ||
| IL268282B2 (en) | hiv inhibitory compounds | |
| HRP20250929T1 (hr) | TERAPIJSKI SPOJEVI ZA INFEKCIJU VIRUSOM HIV-a | |
| CN120053445A (zh) | 用于治疗hiv的衣壳抑制剂 | |
| US20160067255A1 (en) | Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir | |
| JP2017203033A5 (https=) | ||
| JPWO2023102239A5 (https=) | ||
| US20240390349A1 (en) | Dosing regimen of capsid inhibitor | |
| US20250090513A1 (en) | Dosing regimen of hiv capsid inhibitor | |
| Taha et al. | Parenteral patent drug S/GSK1265744 has the potential to be an effective agent in pre-exposure prophylaxis against HIV infection | |
| KR102879944B1 (ko) | Hiv 예방용 인테그라제 억제제 | |
| US20190151307A1 (en) | Methods of treating patients co-infected with a virus and tuberculosis | |
| WO2019016679A1 (en) | Combination drug therapy | |
| JPWO2023102529A5 (https=) | ||
| WO2017205585A1 (en) | Combinations and uses treatments thereof | |
| WO2018005909A1 (en) | Combinations and uses and treatments thereof | |
| HRP20191601T1 (hr) | Terapeutski spojevi korisni za profilaktičan ili terapeutski tretman infekcije hiv virusa | |
| JP2004536017A (ja) | カチオン性界面活性剤を含有するポリヌクレオチドワクチンのアジュバント及び製剤とその使用方法 | |
| US20200171039A1 (en) | Combinations and uses and treatments | |
| WO2018051250A1 (en) | Combination comprising tenofovir alafenamide, bictegravir and 3tc | |
| WO2018044853A1 (en) | Combinations and uses and treatments thereof | |
| WO2018042332A1 (en) | Combinations and uses and treatments thereof | |
| Rizza et al. | Novel HIV drugs and drug delivery strategies. A report from the 2018 Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, USA-March 4-7, 2018 | |
| JP2020529461A (ja) | 組み合わせ並びにその使用及び治療 | |
| NZ781550A (en) | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |